Form 4: MiNK Therapeutics Director Granted RSUs as Compensation

MiNK Therapeutics Director Barbara Ryan received 1,281 restricted stock units as compensation, vesting one month from the grant date of September 2, 2025.

Summary

• Director Barbara Ryan of MiNK Therapeutics, Inc. (INKT) was granted 1,281 restricted stock units (RSUs).
• These RSUs were received in lieu of cash retainers for board and committee compensation.
• Each RSU represents a contingent right to receive one share of Common Stock.
• The grant date for these RSUs is September 2, 2025, with a price of $13.86 per RSU.
• The RSUs will vest one month from the grant date.
• Following this transaction, Barbara Ryan beneficially owns 20,805 shares of Common Stock.

Sentiment

Score: 5

Explanation: This is a routine Form 4 filing detailing director compensation, which is generally neutral in sentiment. It reflects standard corporate governance practices.

Positives

• Granting of RSUs aligns the director's interests with long-term shareholder value.
• Using RSUs in lieu of cash retainers conserves company cash.

Future Outlook

The RSUs are set to vest one month from the grant date, indicating a future transfer of shares.

Industry Context

Routine equity compensation for directors is a common practice in the biotechnology and pharmaceutical industry, aligning executive and board interests with long-term company performance.

Comparison to Industry Standards

• The practice of granting restricted stock units (RSUs) as part of director compensation is a standard corporate governance practice across various industries, including biotechnology.
• Many companies, such as Biogen Inc. or Gilead Sciences, utilize equity-based compensation to align director incentives with shareholder value.
• The specific number of RSUs and their value would typically be benchmarked against peer companies of similar market capitalization and stage of development to ensure competitive and appropriate compensation.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to a director as compensation is a related party transaction, as it involves a transaction between the company and a member of its board.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's interests with long-term shareholder value. The use of RSUs instead of cash conserves company liquidity.

Next Steps

• The RSUs will vest one month from the grant date of September 2, 2025.

Key Dates

Keywords

MiNK Therapeutics, INKT, Form 4, Restricted Stock Units, RSUs, Director Compensation, Equity Grant, Insider Transaction, Barbara Ryan